FDA Generics Process Not Bound By 'Fairness,' DC Circ. Told

Law360, New York (February 5, 2013, 4:25 PM ET) -- The U.S. Food and Drug Administration on Friday urged the D.C. Circuit to reverse a court order forcing it to approve a generic medication produced by Watson Laboratories Inc., saying the ruling was grounded not in law but rather in vague notions of “fairness.”

In its brief, the FDA argued that a district judge blocked its decision to deny 180-day marketing exclusivity to Watson for a version of diabetes drug Actos and instead grant it to Mylan Pharmaceuticals Inc. solely because the outcome seemed inequitable....
To view the full article, register now.

Dewey Verdict Watch

Follow our exclusive coverage of the trial of the year:

Click here for the latest